Clinical trial
Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The…
NCT00259987 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00259987 |
|---|---|
| Title | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus |
| Official title | A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients With Relapsed Adenocarcinoma of the Esophagus, Including Tumors of the Gastroesophageal Junction and Gastric Cardia |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Lapatinib (GW572016) oral tablets |
| Enrollment | 24 |
| Start date | Nov 1, 2005 |
| Completion | May 1, 2007 |
| First posted | Dec 1, 2005 |
| Last update posted | May 18, 2009 |
| Countries | Netherlands, Peru, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: